FDA Rejects Summit's Ivonescimab Lung Cancer Filing; SMMT Shares Fall 16.47%
The FDA wants an overall survival gain that passes a statistical test before it approves ivonescimab in EGFR-mutated lung cancer. Summit shares closed Monday at $11.82, down 16.47% from Friday, on volume 4.7 times the 10-day average.

Summit Therapeutics Inc. (NASDAQ: SMMT) said Sunday, Nov. 15, that the FDA issued a complete response letter, meaning it cannot approve the company's ivonescimab application in its present form. The application covers previously treated, EGFR-mutated non-small cell lung cancer. The release came out at 9:01 a.m. ET on a weekend, and Summit filed it in an 8-K at 6:08 a.m. ET Monday.
A specific FDA objection hits an already falling stock
The letter stops approval of ivonescimab on this application as filed, and shares closed Monday 16.47% below Friday's close. The FDA's objection is narrow: it wants an overall survival gain that passes a statistical test, and the HARMONi trial did not show one in its primary analysis. The stock had also fallen for several sessions before the letter became public.
Shares gapped down, bounced, then faded
Monday's pre-market was the first chance to trade on the news. Summit closed Friday, Nov. 13, at $14.15. In pre-market trading (the session before the 9:30 a.m. ET open), shares fell as low as $9.00 and were at $12.74 when it ended, down 9.96% from Friday's close, on 1.93 million shares.
In the regular session shares rose as high as $13.28, then slipped and closed at $11.82, down 7.22% from the pre-market close. Volume was 21.58 million shares, against a 10-day average of 5.10 million. In after-hours trading, shares were at $12.00, up 1.52% from the close, on only 29,147 shares at 4:45 p.m. ET.
The slide began before the letter. The stock peaked at an intraday high of $18.15 on Nov. 9 (it closed that day at $17.84), then slipped 0.06% on Nov. 10 and fell 6.67% on Nov. 11, 9.41% on Nov. 12 and 6.14% on Nov. 13. It is not clear what drove that earlier drop.
The survival data behind the sell-off
According to the company, the FDA concluded that evidence of effectiveness is not established without an overall survival (OS, how long patients live) improvement that passes a statistical test. The agency said a progression-free survival (PFS, time before the cancer worsens) benefit alone does not support a positive benefit-risk profile.
HARMONi had two primary endpoints. It met PFS, but in the primary OS analysis ivonescimab plus chemotherapy showed a positive trend that did not pass the statistical test. Summit said no FDA-approved regimen has shown an OS benefit that passes a statistical test in this setting.
Two firms cut price targets on Monday. Evercore ISI kept an Outperform rating and lowered its target to $33. Barclays kept Equal-Weight and lowered its target to $18.
Summit's market value was about $11.32 billion. The 21.58 million shares traded in the regular session equal about 14% of the 154.22 million-share float (the shares available to trade).
What Summit points to
The company cited later data and its wider program:
- In a post-hoc analysis (run after the main analysis) with longer follow-up, the OS hazard ratio was 0.76 for all patients, for the Asian patients and for the western patients.
- Treatment-related adverse events led 16 patients (7.3%) to stop ivonescimab and 11 patients (5.0%) to stop placebo. Four patients (1.8%) on ivonescimab plus chemotherapy and five (2.3%) on chemotherapy alone died of treatment-related events.
- Chairman and Co-Chief Executive Officer Robert Duggan said that with five positive Phase III studies between Summit and Akeso, "nothing changes" in the company's belief in ivonescimab.
Summit is running other ivonescimab studies: HARMONi-3 and HARMONi-7 in first-line lung cancer, HARMONi-GI3 in colorectal cancer, HARMONi-GU1 in urothelial carcinoma and a Phase II renal cell carcinoma trial. It also plans combination work with AstraZeneca, Daiichi Sankyo and Revolution Medicines.
What to watch next
- Summit's next regulatory step on ivonescimab. The company said it is now addressing the issues the FDA raised to decide how to proceed.
- Progress in HARMONi-3 and HARMONi-7, the Phase III first-line lung cancer studies. No dates are given.
Bottom line
The FDA declined the filing because the survival data did not pass the statistical test. Summit fell to $11.82 from $14.15 in one session, after a slide that began before the letter. After-hours trading was thin and still open at 4:45 p.m. ET, so the read on the aftermath is provisional.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




